If you have ocular hypertension, the pressure inside your eye is above normal. Pressure builds because the eye's fluid, known as the aqueous humor, doesn't drain properly. Ocular hypertension ...

Purpose: To review the literature regarding ocular hypertension following intravitreal antivascular endothelial growth factor therapy, and to propose a novel mechanism for the development of ...

Our purpose is to update the comprehensive ophthalmologist about the results of the Ocular Hypertension Treatment Study and the current clinical management of ocular hypertension. In the Ocular ...

and in its product candidate PAXTRAVA™ (travoprost intracameral implant or OTX-TIC), which is currently in a Phase 2 clinical ...

and in its product candidate PAXTRAVA™ (travoprost intracameral implant or OTX-TIC), which is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.

Ocular Therapeutix, Inc ... in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Follow Ocular on its website, LinkedIn or X. The Ocular Therapeutix ...

According to the company, its Phase 1/2 CLARA trial of AURN001 for corneal edema demonstrated significant dose-dependent ...

in a randomised order in one eye of each of 105 patients with ocular hypertension or glaucoma. Three measurements were made with each method, and by each of two independent GAT observers. GAT ...

The patient’s orbital inflammation and ocular hypertension showed no response to topical and systemic pressure-lowering agents and non-steroidal anti-inflammatory agents but resolved rapidly after the ...

“Since 2007, we have been studying L. barbarum’s neuroprotective effects in a series of ocular hypertension mouse models, as well as in humans with degenerative eye disease,” says So.

The highest dose of Aurion Biotech’s cell therapy, the main component of which recently received approval in Japan, has ...

and in its product candidate PAXTRAVA™ (travoprost intracameral implant or OTX-TIC), which is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.